ClinicalTrials.gg
CompletedNCT05485584Updated Feb 25, 2025

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19

A Phase 2 interventional study of rSIFN-co Nasal Spray and rSIFN-co Nasal Spray in COVID-19 and SARS-CoV-2 Infection, sponsored by Sichuan Huiyang Life Science and Technology Corporation. Completed at 2 sites in Philippines. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Sichuan Huiyang Life Science and Technology Corporation · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in COVID-19 with a site in Philippines — 3 open to participants now, 6 under way, 4 of them phase 3. COVID-19 · Philippines.

Enrollment
30th of 41
188 · median 1,550
Started
2022
with 15 others
Phase 2
6 of 45
none open now
Registered
29th of 45
by date

Among the 45 studies in COVID-19 with a site in Philippines, this one is the 30th largest by enrollment of the 41 interventional ones that give a count, is one of 16 that started in 2022, is one of 6 in phase 2, and was the 29th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 45 studies in COVID-19 with a site in Philippines are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Philippines have not opened yet or have stopped. Only those recruiting at a site in Philippines →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in COVID-19 with a site in Philippines, or all of them as a file.
02

Study summary

This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as well as subjects with mild or asymptomatic COVID-19.

Read the detailed description

Approximately 200 subjects are planned to be enrolled, including 100 healthy subjects and 100 COVID-19 subjects.

For the healthy subjects in close contact with confirmed COVID-19 case(s) (Group A), approximately 100 subjects will be randomized in a 1:1 ratio to receive placebo or rSIFN-co treatment in a double-blind fashion.

For the subjects with mild or asymptomatic COVID-19 (Group B), approximately 100 subjects will also be randomly assigned in a 1:1 ratio to receive institutional or local standard of care (SoC) plus placebo or SoC plus rSIFN-co in a double-blind fashion.

All subjects will receive the study product for 10 days; around 8 million IU (16 μg) or 16 million IU (32 μg) of rSIFN-co will be administered daily. The safety and efficacy parameters will be monitored throughout the study period. Subjects will be instructed to complete a diary to record daily administration of study product, SpO2 level, as well as the occurrence and severity of any clinical symptoms.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 and ≤75 years of age at the time of .
  2. Willing and able to provide written informed consent/assent for the trial.
  3. Healthy subjects in close contact with confirmed COVID-19 case(s) or subjects with mild or asymptomatic COVID-19.

    a. Healthy subjects in close contact with confirmed COVID-19 case(s) i. With exposure to confirmed COVID-19 case(s) within 96 hours (refer to the definition of healthy subjects in close contact with confirmed COVID-19 case[s]), ii. Negative reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 infection, with the sample collected at screening, iii. Have no previous confirmed COVID-19 diagnosis, iv. Without symptoms of respiratory infection, including fever, cough, fatigue, anorexia, shortness of breath, myalgias, sore throat, nasal congestion, headache, gastrointestinal symptoms, loss of smell (anosmia), loss of taste (ageusia), or other symptoms associated with COVID-19, AND v. With stable health status, as judged by the investigator and determined by physical examination, vital signs, medical history, and laboratory tests at screening.

    b. Subjects with mild or asymptomatic COVID-19 i. Meeting the criteria of mild or asymptomatic COVID-19,

    Note:

    • Asymptomatic or presymptomatic infection: Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., PCR) or antigen test, but have no symptoms.
    • Mild disease: Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) and saturation of oxygen (SpO2) ≥90% on room air at sea level, without shortness of breath, dyspnea, or abnormal chest imaging.

    ii. Positive RT-PCR test for SARS-CoV-2 infection, with the sample collected at screening or within 72 hours prior to screening, AND iii. Without evidence of viral pneumonia or hypoxia.

  4. Women of must have a negative pregnancy test result at screening.
  5. Males and females who are fertile must adhere to requirements for the duration of the study.
  6. Non-participation in any other clinical trials during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any of the following conditions that would impair their ability to participate reliably in the trial, or those who may increase the risk to themselves or others by participating

    1. laboratory abnormalities (including a screening test of /alanine aminotransferase (AST/ALT) > 5 times the [ULN] and/or estimated [eGFR] \< 30 mL/min/1.73m2)
    2. Serious medical illnesses (including known history of major hematological, renal, cardiovascular, or hepatic abnormalities that are clinically significant)
    3. Psychological condition or social circumstances
  2. Received an experimental medication within 1 month prior to screening or expect to receive such treatment during the study period.
  3. With or to the study product or any of its component.
  4. Pregnant or lactating women.
  5. Unwilling or unable to follow protocol requirements.
  6. Any condition which in the investigator's opinion deems the potential participant an unsuitable candidate to receive the study product.
  7. Received any interferons and any nasal/pharyngeal sprays within 7 days prior to screening.
  8. Received COVID-19 vaccine within 14 days prior to screening
  9. Had previous confirmed SARS-CoV-2 infection >96 hours prior to being screened for the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Healthy subjects(A1)

    Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Once daily

    Drug: rSIFN-co Nasal Spray

  • Placebo comparator
    Healthy subjects(A2)

    Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Once daily

    Drug: Placebo Nasal Spray

  • Experimental
    COVID-19 subjects(B1)

    Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Twice daily

    Drug: rSIFN-co Nasal Spray

  • Placebo comparator
    COVID-19 subjects(B2)

    Each nostril: 2 sprays/time; Pharynx: 4 sprays/time; Twice daily

    Drug: Placebo Nasal Spray

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of laboratory-confirmed SARS-CoV-2 infection in health subjects

    Incidence of laboratory-confirmed SARS-CoV-2 infection in health subjects over 28 days (Day 1 to Day 28) as assessed by RT-PCR

    Time frame: Day1-Day28

  2. Percentage of subjects with disease progression

    Percentage of subjects with disease progression, defined as progression from asymptomatic/mild to moderate/severe in severity, over 28 days

    Time frame: Day1-Day28

Secondary outcomes

  1. To assess the safety and tolerability profiles of rSIFN-co nasal spray, as assessed by treatment-emergent adverse events (TEAEs)

    TEAEs will be coded using the Medical Dictionary for Drug Regulatory Affairs (MedDRA®, version 24.1 or later) and presented as summary tabulations, including categorical information of interest such as severity, causal relationship to study medication, and action taken.

    Time frame: Day1-Day28

  2. Percentage of subjects discontinuing from study product due to TEAE during the treatment period

    All AEs will be assessed by the Investigator using the CTCAE version 5.0.

    Time frame: Day1-Day10

  3. Percentage of subjects who develop to moderate or severe COVID-19 (WHO definition) over 28 days

    For healthy subjects only

    Time frame: Day1-Day28

  4. Incidence of COVID-19-related complications over 28 days

    For healthy subjects only

    Time frame: Day1-Day28

  5. Time to clearance of SARS-CoV-2

    For COVID-19 subjects only. It defined as 2 consecutive negative swabs (sampling interval ≥24 hours)

    Time frame: Day1-Day28

  6. Percentage of subjects who require supplemental oxygen or mechanical ventilation

    For COVID-19 subjects only.

    Time frame: Day1-Day28

  7. Percentage of subjects with clinical improvement

    For COVID-19 subjects only. It defined as a decrease of at least one point per the 11-point WHO clinical progression scale compared to baseline, on Days 5 and 10

    Time frame: Day1-Day10

  8. Time to clinical improvement from the highest outcome scores per 11-point WHO clinical progression scale

    For COVID-19 subjects only.

    Time frame: Day1-Day28

  9. Time to resolution of all symptoms present at baseline

    For COVID-19 subjects only.

    Time frame: Day1-Day28

07

Study locations

2 sites
  • GreenCity Medical Center
    San Fernando, Central Luzon, Philippines
  • Medical Center Manila
    Manila, Philippines
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2023, 9 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 9 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2022
First posted
Aug 3, 2022
StartActual
Jul 1, 2022
Primary completionActual
Apr 5, 2023
CompletionActual
Apr 5, 2023
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05485584
Lead sponsor
Sichuan Huiyang Life Science and Technology Corporation
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Jul 1, 2022
Primary completion
Apr 5, 2023
Completion
Apr 5, 2023
Last update
Feb 25, 2025

Study contacts

GW WEI
study director · Sichuan Huiyang Life Science and Technology Corporation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interferon alfacon-1 · Recombinant Super-compound Interferon

Start the discussion